Shane Schmidt’s $8.2M Pandemic Stock Scheme

The first wave of COVID-19 fear swept through America in March 2020 like nothing in living memory. Stock markets cratered. Businesses shuttered. And in the chaos, a handful of operators saw not catastrophe but opportunity—a chance to exploit panic, deploy shell companies, and dump worthless stock on desperate investors hunting for the next miracle cure or protective equipment supplier.

Shane Schmidt was allegedly one of them.

By the time federal investigators pieced together the scheme, Schmidt and four co-conspirators had orchestrated what the Securities and Exchange Commission would describe as a “microcap fraud” tied directly to pandemic chaos—a fraudulent operation designed to conceal identities while illegally dumping company stock on unsuspecting buyers. The final tally: over $12 million in penalties and disgorgement across all defendants, with Schmidt personally facing an $8.2 million judgment. But the numbers only hint at the mechanics of deception—a labyrinth of offshore entities, nominee shareholders, and market manipulation that exploited the single greatest public health crisis in a century.

The case would eventually be filed in federal court as SEC v. Gomes et al., Case No. 1:20-cv-11092, with Schmidt named alongside Nelson Gomes, Douglas Roe, Michael Luckhoo-Bouche (sometimes spelled Luckhoo-Bouch in court filings), and Kelly Warawa. Together, they faced charges under some of the most fundamental provisions of securities law: Section 10(b) of the Securities Exchange Act of 1934, Section 17(a) of the Securities Act of 1933, and Section 13(d) disclosure requirements. The violations spanned registration fraud, disclosure fraud, and market manipulation—a trifecta of deception in the microcap world.

What emerged from the SEC’s complaint and subsequent court orders was a portrait of sophisticated fraud machinery operating precisely when regulators were stretched thin and investors were most vulnerable.

The Microcap Underworld

To understand Schmidt’s alleged role, you need to understand microcap stocks—the penny-stock universe where most retail investors never venture and where regulatory scrutiny has historically been thin.

Microcap companies are the smallest publicly traded firms, typically worth less than $300 million and often far less. Many trade over-the-counter rather than on major exchanges. Their stocks can cost pennies. They file minimal disclosure. Liquidity is sparse. And precisely because they operate in this shadowy space between private startups and real public companies, microcaps have always attracted fraudsters.

The classic microcap scheme involves “pump and dump”—fraudsters accumulate shares in a dormant shell company, hype the stock through false press releases or paid promotions, then dump their shares on buyers lured by the artificially inflated price. When the hype stops, the price collapses, leaving retail investors holding worthless paper.

But Schmidt and his co-defendants allegedly ran a more sophisticated variant. Instead of merely pumping worthless stocks, they allegedly built a business model around concealing the true ownership and control of stock positions—allowing them to dump shares without triggering the disclosure requirements that normally alert the market when insiders or major shareholders are selling. They operated, in essence, a fraud-as-a-service model for the microcap underworld.

And when COVID-19 hit, the scheme found its perfect environment.

The Pandemic Gold Rush

March and April 2020 were months of sheer market chaos. Major indices fell 30 percent in weeks. Investors desperate for protection or profit poured into anything that promised pandemic solutions—vaccine developers, mask manufacturers, testing companies, telemedicine platforms.

Many of these companies were legitimate. But others were shells, rebranded overnight from failed mining ventures or dormant holding companies into “COVID-19 solution providers.” Press releases announced pivot strategies. Websites suddenly featured stock photos of laboratories. And microcap stock prices—previously trading at fractions of a penny—suddenly spiked on enormous volume as retail investors, locked at home and trading on Robinhood, chased the next ten-bagger.

The SEC was overwhelmed. Enforcement attorneys were working from kitchen tables. Document review slowed. And while the Commission issued investor alerts warning about COVID-19 stock scams, the agency couldn’t possibly monitor every thinly traded microcap shell that suddenly claimed to have pivoted into hand sanitizer production or PPE supply.

It was into this environment that Schmidt and his co-defendants allegedly deployed their scheme.

According to the SEC’s complaint, the defendants operated what amounted to an identity-concealment service. They used foreign entities, nominee shareholders, and carefully structured transactions to allow the true owners of stock positions to remain hidden—evading the Section 13(d) disclosure requirements that mandate public filing when any person or group acquires more than 5 percent of a public company’s shares.

These disclosure rules exist for a reason. When a large shareholder accumulates a position, the market deserves to know—because that shareholder may be planning to take control of the company, influence management, or simply dump a massive position. Section 13(d) filings, known as “beneficial ownership reports,” are supposed to provide transparency.

But Schmidt’s operation allegedly subverted that transparency entirely.

The Machinery of Concealment

The SEC’s complaint describes a multi-layered structure designed to obscure the real players.

At the core were shell companies and nominee arrangements. Gomes, Roe, Luckhoo-Bouche, Warawa, and Schmidt allegedly worked in concert to acquire stock positions in microcap companies—not for investment, but for resale. The scheme required hiding who actually controlled those shares, because if the true owners were revealed, their subsequent sales would trigger legal scrutiny and tank the stock price.

So they allegedly used “nominees”—individuals or entities who held stock in their own names but were actually controlled by the defendants. On paper, the shares belonged to the nominees. In reality, Schmidt and his co-conspirators allegedly called the shots, deciding when to sell and pocketing the proceeds.

This structure allowed the defendants to conduct unregistered stock sales in violation of Sections 5(a) and 5(c) of the Securities Act, which require that securities be registered with the SEC before being sold to the public—unless an exemption applies. Legitimate companies register their offerings, providing investors with prospectuses and financial disclosures. But shell companies in pump-and-dump schemes almost never do. Instead, they issue shares in private transactions, then claim exemptions that don’t actually apply, and dump the stock on the open market through complicit brokers.

The SEC alleged that Schmidt and his co-defendants violated these registration requirements repeatedly—selling stock without proper registration and without valid exemptions.

But the fraud went deeper. The defendants also allegedly violated the antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5—the securities law equivalent of a general prohibition on lying, cheating, or defrauding investors. Specifically, Rules 10b-5(a) and (c) prohibit engaging in any scheme to defraud or any act that operates as a fraud in connection with the purchase or sale of securities.

By concealing the true ownership of stock, the defendants allegedly defrauded the market itself. Investors buying shares had no idea they were purchasing from undisclosed insiders who controlled the supply and were systematically dumping their positions. The prices were artificial. The liquidity was illusory. And when the selling stopped, the stocks collapsed, leaving retail buyers with worthless holdings.

The complaint also alleged violations of Section 17(a)(1) and 17(a)(3) of the Securities Act, which similarly prohibit fraud in the offer or sale of securities. These provisions don’t require proof of intent—negligence or recklessness is enough. And the SEC argued that Schmidt and his co-defendants acted at least recklessly, if not knowingly, in orchestrating a scheme built on deception.

The COVID-19 Connection

What made this scheme particularly egregious was its timing. The SEC’s enforcement action explicitly tagged the case as “COVID-19” fraud—indicating that the defendants allegedly exploited pandemic-related market conditions.

Court documents don’t spell out every detail, but the pattern is recognizable. In the spring of 2020, microcap stocks claiming some connection to COVID-19 saw massive speculative interest. A dormant shell company could issue a press release announcing a partnership with a mask supplier or a pivot into telehealth, and its stock would triple in a day on volume in the millions.

For Schmidt and his co-conspirators, this environment was ideal. High volume meant they could dump large positions without moving the price too much. Frenzied buying meant less scrutiny of who was selling. And regulatory attention was focused on more visible targets—large-cap companies with accounting problems or well-known Ponzi schemes.

The defendants allegedly positioned themselves as middlemen in this chaos—acquiring stock in pandemic-related microcaps, concealing their ownership, and selling into the buying frenzy. They weren’t promoting the stocks themselves, necessarily. They didn’t need to. The market was doing that for them. They just needed to stay hidden long enough to unload their positions.

And for a time, it worked.

The Players

Shane Schmidt’s exact role in the conspiracy remains somewhat opaque in publicly available filings, but his $8.2 million judgment suggests he was a central figure—possibly the largest beneficiary or a key architect of the scheme.

Co-defendant Nelson Gomes appears in the case title, suggesting he may have been a principal defendant or the first named. Douglas Roe, Michael Luckhoo-Bouche, and Kelly Warawa round out the list. The SEC complaint describes them collectively as operating a “fraudulent business to conceal identities while illegally dumping company stock.”

What’s notable is the absence of detailed biographical information in the public record. Unlike many white-collar defendants—lawyers, executives, financial advisors with LinkedIn profiles and community ties—Schmidt and his co-defendants left faint digital footprints. This itself may be telling. Microcap fraud operators often work in the shadows, using offshore entities and pseudonyms, cycling through shell companies faster than regulators can track them.

The complaint doesn’t specify how the defendants knew each other or how the operation was structured. Were they a tight-knit crew running a boiler room, or a loose network of facilitators each playing a specialized role? Did Schmidt handle the offshore entities while others managed nominee accounts? Was there a ringleader, or was this a partnership of equals?

What’s clear is that the SEC believed they acted in concert—a critical finding, because it allowed the agency to pursue them as a group under aiding-and-abetting theories and joint-and-several liability.

The Unraveling

The SEC’s investigation likely began with trading surveillance. Microcap fraud often leaves patterns: sudden spikes in volume, unexplained stock issuances, and selling by undisclosed parties. Regulators use data analytics to flag suspicious activity, then dig into stock transfer records, broker accounts, and corporate filings.

Someone at the SEC’s Division of Enforcement likely noticed irregularities in the trading of one or more microcap stocks—perhaps pandemic-related tickers that surged in March or April 2020, then collapsed after massive unregistered selling. From there, investigators would have subpoenaed brokerage records, interviewed transfer agents, and traced the flow of shares.

What they found, according to the complaint, was a network of nominee accounts and foreign entities all controlled by Schmidt and his co-defendants. The paper trail—wire transfer records, emails, corporate resolutions—allegedly revealed that the nominees were shams, that the defendants were the true beneficial owners, and that they had systematically evaded disclosure and registration requirements.

The SEC filed its complaint on an unspecified date in 2020, in the U.S. District Court for the Southern District of New York, under Case No. 1:20-cv-11092. The enforcement action came together quickly by SEC standards—suggesting the evidence was strong and the defendants may have left a clear trail.

By December 9, 2020, the SEC announced it had secured final judgments against all five defendants. The speed of resolution—less than a year from the fraud’s peak to final judgment—suggests the defendants did not mount a protracted defense. They may have settled, agreed to consent judgments, or been hit with default judgments after failing to respond.

The Judgment

The final judgments, announced in SEC Litigation Release No. 24979, were substantial. Across all five defendants, the SEC secured over $12 million in penalties and disgorgement.

Shane Schmidt personally faced an $8.2 million judgment—the largest individual amount mentioned in the release. This figure likely represents a combination of disgorgement (the ill-gotten gains from the scheme) and civil penalties (punitive fines).

Under securities law, disgorgement is meant to strip defendants of their profits, restoring them to the position they would have been in had they never committed fraud. Civil penalties, meanwhile, are punitive—designed to deter future violations. The SEC has three tiers of penalties depending on the severity of the fraud. For individuals, the maximum per violation can reach hundreds of thousands of dollars, and in cases involving substantial monetary harm, penalties can climb into the millions.

Schmidt’s $8.2 million judgment suggests either a massive ill-gotten gain or multiple violations across numerous transactions—or both. Given that the total across all defendants exceeded $12 million, and Schmidt’s share was $8.2 million, he appears to have been the primary beneficiary of the scheme.

What happened to the money? SEC judgments often go unpaid. Defendants hide assets offshore, declare bankruptcy, or simply vanish. The SEC can refer cases to the Department of Justice for criminal prosecution or to the U.S. Marshals for asset seizure, but collection rates on civil judgments are notoriously low, especially in microcap fraud cases where defendants have planned their exits.

Whether Schmidt paid any portion of the judgment, whether he surrendered assets, or whether he simply walked away is not disclosed in the public record.

The Victims

The SEC’s enforcement actions rarely detail individual victims, but the impact of microcap fraud is well-documented. Retail investors—often retirees, small-time traders, or people hoping to build wealth outside traditional 401(k)s—lose everything when pump-and-dump schemes collapse.

In the pandemic environment, the losses were likely compounded by desperation. People out of work, afraid, looking for any way to protect their families or recoup losses, poured money into stocks that promised COVID-19 solutions. They didn’t know they were buying from hidden insiders dumping stock through undisclosed channels.

When the selling stopped and the stock prices collapsed, those retail investors held shares worth pennies or nothing. There was no recovery fund, no insurance, no way to reverse the transaction. The money was gone—cycled through offshore accounts, layered through shell companies, and ultimately into the pockets of Schmidt and his co-conspirators.

This is the human cost of microcap fraud: not corporate balance sheets or institutional portfolios, but individual people losing savings they couldn’t afford to lose.

The Bigger Picture

Schmidt’s case was one of dozens of COVID-19-related enforcement actions the SEC pursued in 2020 and 2021. The pandemic created a perfect storm for securities fraud: market volatility, regulatory distraction, and an influx of novice retail investors trading from home.

Microcap fraud, in particular, surged. The SEC’s Office of Investor Education and Advocacy issued multiple alerts warning investors about “COVID-19-related investment scams,” noting that fraudsters were promoting stocks of companies claiming to manufacture PPE, develop vaccines, or provide testing services—often with no actual operations.

Some schemes were crude—cold calls and spam emails. But others, like Schmidt’s alleged operation, were sophisticated, involving offshore structures, nominee accounts, and careful legal maneuvering to evade disclosure.

The SEC’s response was aggressive. The Commission suspended trading in dozens of microcap stocks, filed emergency enforcement actions, and secured asset freezes. But the sheer volume of suspicious activity overwhelmed the agency’s resources. For every case like Schmidt’s that resulted in a judgment, dozens of others likely went undetected or unprosecuted.

Legal Precedent and Statutory Framework

Schmidt’s case illustrates the breadth of the SEC’s enforcement toolkit. The charges spanned multiple statutory provisions, each targeting a different aspect of the fraud.

Section 10(b) and Rule 10b-5 are the SEC’s primary antifraud weapons. Section 10(b) makes it unlawful to use “any manipulative or deceptive device” in connection with the purchase or sale of securities. Rule 10b-5, promulgated under Section 10(b), prohibits making false statements, omitting material facts, and engaging in fraudulent schemes. These provisions are intentionally broad, allowing the SEC to pursue nearly any form of securities fraud.

Section 17(a) of the Securities Act similarly prohibits fraud in the offer or sale of securities, but with a key difference: it doesn’t require proof of scienter (intent to deceive) for subsections (a)(2) and (a)(3). Negligence or recklessness is enough. This makes Section 17(a) a powerful tool in cases where defendants claim they didn’t know their conduct was illegal.

Sections 5(a) and 5(c) of the Securities Act require registration of securities offerings unless an exemption applies. These are strict liability provisions—if you sell unregistered securities without a valid exemption, you’ve violated the law, regardless of intent. Schmidt and his co-defendants allegedly sold stock without registration and without qualifying for any exemption, making this a straightforward violation.

Section 13(d) and Rule 13d-1 require beneficial owners of more than 5 percent of a public company’s stock to file a public disclosure within ten days. This rule is meant to provide transparency about who controls significant stakes in public companies. By allegedly using nominees to conceal their ownership, Schmidt and his co-defendants evaded this requirement, defrauding the market and allowing them to dump stock without warning.

The cumulative effect of these violations was a comprehensive fraud—registration violations, disclosure violations, and outright market manipulation. The SEC threw the book at Schmidt, and the court’s $8.2 million judgment reflected the seriousness of the conduct.

The Aftermath

By late 2020, the SEC had secured final judgments against all five defendants. The case largely disappeared from public view after that. No criminal charges appear to have been filed, though the SEC often refers cases to the Department of Justice for parallel prosecution. Whether Schmidt faced criminal investigation or prosecution is unknown.

What is known is that Schmidt’s name is now permanently linked to pandemic fraud, microcap manipulation, and an $8.2 million judgment. A Google search for “Shane Schmidt SEC” surfaces the enforcement action, the complaint, and the court orders. For anyone conducting due diligence—employers, investors, business partners—the case is a red flag.

The broader impact of the case is harder to measure. Did it deter other microcap fraud operators? Did it reassure investors that the SEC was watching? Did it recover any money for victims?

The answer to all three is probably no. Microcap fraud continues to thrive, enforcement resources remain limited, and victim recovery in these cases is rare. But the case did serve a symbolic function: even in the chaos of a pandemic, even in the shadowy world of microcap stocks, the SEC could still identify fraud, build a case, and secure a judgment.

Unanswered Questions

Much about the Schmidt case remains opaque. The public record provides the legal framework—the statutes violated, the penalties imposed—but little of the human detail that makes fraud cases resonate.

Who were the victims? How much did they lose individually? Did any of them come forward, or did they simply absorb the loss and move on?

What happened to the $8.2 million judgment? Did Schmidt pay? Did the SEC seize assets, or is the judgment uncollectible?

Where is Shane Schmidt now? Is he barred from the securities industry? Did he face criminal charges? Has he resurfaced in another business, another scheme?

And what about the co-defendants—Gomes, Roe, Luckhoo-Bouche, Warawa? What were their individual roles, their individual penalties, their individual fates?

The SEC’s enforcement machinery is built for deterrence, not transparency. Cases are resolved through consent judgments, sealed settlements, and undisclosed agreements. The public gets the headline—“SEC Secures $12 Million Judgment in COVID-19 Fraud Case”—but rarely the full story.

For Schmidt, the judgment is likely permanent. SEC enforcement actions follow defendants for life, showing up in background checks, investor databases, and regulatory filings. Even if he paid nothing, even if he never spent a day in court, the judgment stands as a public record of fraud.

The Enduring Lesson

Shane Schmidt’s case is a reminder that fraud doesn’t pause for pandemics—it accelerates. When fear and uncertainty grip markets, when regulatory scrutiny is stretched thin, when millions of desperate investors flood into speculative assets, fraudsters see opportunity.

The microcap world has always been a wild frontier, a place where fortunes are made and lost on rumors, where shell companies outnumber real businesses, and where the line between aggressive promotion and outright fraud is razor-thin. Schmidt and his co-defendants allegedly crossed that line, building a business model around concealment and deception, then deploying it into a market paralyzed by a once-in-a-century crisis.

They were caught, judged, and fined. But the money is likely gone, the victims uncompensated, and the defendants possibly operating under new names in new schemes. That’s the reality of microcap fraud: enforcement is slow, recovery is rare, and justice is incomplete.

The SEC’s case against Shane Schmidt will stand as a record of what happened in those frenzied months of 2020, when the world was locked down and the markets were wide open. It’s a record written in legal filings and court orders, in statutes and penalties—a story of fraud in the time of plague, of opportunism in the midst of fear, and of a system that, however imperfectly, eventually caught up.

For now, that record is all we have. The rest remains hidden in offshore accounts, sealed settlements, and the silence of defendants who learned long ago that in the world of microcap fraud, the less you say, the better.